NCT04419688 is a Phase 1 clinical trial of STT-5058 in Hypertriglyceridemia, sponsored by Staten Biotechnology BV.

Who is sponsoring NCT04419688?

NCT04419688 is sponsored by Staten Biotechnology BV.

What drugs are being tested in NCT04419688?

Interventions in NCT04419688: STT-5058, Placebo.

What condition does NCT04419688 study?

NCT04419688 studies Hypertriglyceridemia.

Is NCT04419688 still recruiting?

NCT04419688 is currently terminated. Last updated 23 January 2023.

Last reviewed 2023-01-23 · How we verify

NCT04419688

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A First in Human Study of STT-5058, an Antibody That Binds ApoC3

Terminated Phase 1 Last updated 23 January 2023

What this trial tests

Phase 1 trial testing STT-5058 in Hypertriglyceridemia in 93 participants. Terminated before completion.

Timeline

26 May 2020

Primary endpoint
23 December 2022

23 December 2022

Quick facts

Lead sponsor	Staten Biotechnology BV
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	93
Start date	26 May 2020
Primary completion	23 December 2022
Estimated completion	23 December 2022
Sites	1 location across United Kingdom

Drugs / interventions tested

STT-5058 — full drug profile →
Placebo

Conditions studied

Hypertriglyceridemia — all drugs for Hypertriglyceridemia →

Sponsor

Staten Biotechnology BV — full company profile →

Who can join

Adults 18 to 65, any sex, with Hypertriglyceridemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A First in Human Study of STT-5058, an Antibody That Binds ApoC3, investigating single and multiple ascending intravenous doses and ascending subcutaneous doses of STT-5058 in otherwise healthy volunteers with elevated triglyceride levels

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance.
Packard CJ, Pirillo A, Tsimikas S, Ference BA, et al · · 2024 · cited 33× · PMID 38039351 · DOI 10.1093/cvr/cvad177
Managing of Dyslipidaemia Characterized by Accumulation of Triglyceride-Rich Lipoproteins.
Visser J, van Zwol W, Kuivenhoven JA. · · 2022 · cited 7× · PMID 35107764 · DOI 10.1007/s11883-022-00979-y

Verify or expand the search:

Other recruiting trials for Hypertriglyceridemia

Currently open trials in the same condition.

NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07004777 — Effect of Consuming n-3 Polyunsaturated Fatty Acids Rich Foods on Triglyceride Concentration and Lipoprotein Composition · NA · recruiting
NCT07140809 — a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia · Phase 1, PHASE2 · recruiting
NCT06494488 — Differential Thrombogenesis by EPA and DHA Mediated by HDL · EARLY_PHASE1 · recruiting
NCT06783881 — Single-ascending Dose Study of Kylo-12 in Healthy Subjects · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04419688 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Staten Biotechnology BV
Last refreshed: 23 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04419688.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing